Compare AVA & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVA | TLX |
|---|---|---|
| Founded | 1889 | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.6B |
| IPO Year | 1994 | N/A |
| Metric | AVA | TLX |
|---|---|---|
| Price | $41.52 | $9.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $39.00 | $21.13 |
| AVG Volume (30 Days) | ★ 442.1K | 100.2K |
| Earning Date | 05-05-2026 | 08-19-2026 |
| Dividend Yield | ★ 4.84% | N/A |
| EPS Growth | ★ 3.93 | N/A |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $1,964,000,000.00 | N/A |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | $4.44 | N/A |
| P/E Ratio | ★ $36.91 | $150.33 |
| Revenue Growth | ★ 1.34 | N/A |
| 52 Week Low | $35.50 | $6.28 |
| 52 Week High | $43.50 | $18.13 |
| Indicator | AVA | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 37.39 |
| Support Level | $40.08 | $9.46 |
| Resistance Level | $42.02 | $9.92 |
| Average True Range (ATR) | 0.69 | 0.29 |
| MACD | 0.05 | -0.17 |
| Stochastic Oscillator | 93.24 | 2.96 |
Avista Corp is an electric and natural gas utility company. The company has two business segments including Avista Utilities, which provides electric distribution and transmission, and natural gas distribution services in parts of eastern Washington and northern Idaho, and also provides natural gas distribution service in parts of northeastern and southwestern Oregon. Avista Utilities has electric generating facilities in Washington, Idaho, Oregon, and Montana. AEL&P segment is a regulated utility providing electric services in Juneau, Alaska that is a wholly-owned subsidiary and the primary operating subsidiary of AERC.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.